Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

ImmunoGen shares plummet by 32% after FDA recommends new Phase 3 trial

pharmafileMay 17, 2019

Tag: FDA , Immunogen , trial

PharmaSources Customer Service